CasZyme and Cirena Partner for CRISPR Optimization
The biotech firms are collaborating to improve the editing efficiency of the Cas12l CRISPR nuclease using synthetic guide RNAs.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you believe new genetic engineering breakthroughs will likely improve the quality of medical treatments?
Biotech companies CasZyme and Cirena have signed a collaboration agreement to advance gene editing capabilities. They plan to optimize the Cas12l CRISPR nuclease by utilizing synthetic long guide RNAs.
Why it matters
The partnership aims to develop scalable, reproducible, and chemically defined reagents for Cas12l nucleases. This technical development is essential for the successful therapeutic translation of gene-editing therapies.
Cirena produces synthetic guide RNAs ranging from 100 to 300 nucleotides with at least 90 percent purity. The collaboration focuses on testing guides near the 160-nucleotide length required for optimal Cas12l nuclease performance.
The players
CasZyme
Based in Vilnius, Lithuania, this biotechnology company specializes in developing CRISPR-based molecular tools including the Cas12l nuclease.
Cirena
Headquartered in Boulder, Colorado, this company utilizes a platform to manufacture high-purity synthetic RNA for diverse biotech applications.
The details
CasZyme will benchmark Cirena synthetic guides against standard IVT guides using primary human T cells. The teams will conduct RNP assembly optimization and deliver the components into cells to measure on-target editing outcomes via next-generation sequencing.
Timeline
CasZyme and Cirena signed their collaboration agreement on October 26, 2026.
Editing-efficiency and viability results are expected in early 2027.
The Tech Race
This collaboration marks a technical shift in how the Cas12l CRISPR nuclease is deployed, moving away from conventional production methods to synthetic platforms. By replacing standard IVT guides with high-purity synthetic RNA, the partnership addresses a critical bottleneck in scalable gene editing.
For researchers and biotech developers, this partnership may simplify the workflow for producing reliable CRISPR reagents. If successful, the move toward chemically defined, high-purity guides could improve the consistency and reproducibility of future gene-editing treatments.
The takeaway
Reliable synthetic reagents are a vital component in the transition of CRISPR technologies from the lab to clinical settings. Standardizing guide RNA production helps ensure that gene-editing therapies remain consistent throughout the manufacturing process.
What happens next
The companies expect to report initial editing-efficiency and cell viability results in early 2027.
Further reading
Learn more about the latest industry trends in the Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe new genetic engineering breakthroughs will likely improve the quality of medical treatments?
